3 results
Approved WMOCompleted
To estimate the efficacy of erlotinib administered as a single agent to chemo-naïve NSCLC patients as determined by the non progression rate (NPR) at 8 weeks.
Approved WMOCompleted
The objective of this study is to evaluate the safety and device performance of the Portaero Pneumostoma System to create and maintain a transthoracic pneumostoma in patients with severe emphysema and hyperinflation.
Approved WMORecruiting
the primary objective of our study is to define a set of patient characteristics that can predict the effectiveness of an MRA in treating symptomatic OSA. The aim of our study is to develop a prediction model to calculate the success rate in an…